EXTENDICARE INC (EXE.CA) Stock Fundamental Analysis

Canada • Toronto Stock Exchange • TSX:EXE • CA30224T8639

23.99 CAD
-0.22 (-0.91%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall EXE gets a fundamental rating of 6 out of 10. We evaluated EXE against 14 industry peers in the Health Care Providers & Services industry. While EXE belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. EXE is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year EXE was profitable.
  • EXE had a positive operating cash flow in the past year.
  • Each year in the past 5 years EXE has been profitable.
  • In the past 5 years EXE always reported a positive cash flow from operatings.
EXE.CA Yearly Net Income VS EBIT VS OCF VS FCFEXE.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 10.41%, EXE belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
  • The Return On Equity of EXE (55.53%) is better than 92.86% of its industry peers.
  • EXE has a better Return On Invested Capital (18.54%) than 100.00% of its industry peers.
  • EXE had an Average Return On Invested Capital over the past 3 years of 11.40%. This is above the industry average of 7.74%.
  • The last Return On Invested Capital (18.54%) for EXE is above the 3 year average (11.40%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 10.41%
ROE 55.53%
ROIC 18.54%
ROA(3y)8.13%
ROA(5y)6.26%
ROE(3y)56.07%
ROE(5y)44.35%
ROIC(3y)11.4%
ROIC(5y)10.15%
EXE.CA Yearly ROA, ROE, ROICEXE.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

1.3 Margins

  • Looking at the Profit Margin, with a value of 5.72%, EXE belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
  • EXE's Profit Margin has improved in the last couple of years.
  • With a decent Operating Margin value of 8.22%, EXE is doing good in the industry, outperforming 78.57% of the companies in the same industry.
  • In the last couple of years the Operating Margin of EXE has grown nicely.
  • EXE has a Gross Margin of 14.15%. This is in the lower half of the industry: EXE underperforms 78.57% of its industry peers.
  • EXE's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 8.22%
PM (TTM) 5.72%
GM 14.15%
OM growth 3Y21.21%
OM growth 5Y10.26%
PM growth 3Y73.29%
PM growth 5Y15.22%
GM growth 3Y6.44%
GM growth 5Y3.11%
EXE.CA Yearly Profit, Operating, Gross MarginsEXE.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), EXE is creating value.
  • EXE has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for EXE has been reduced compared to 5 years ago.
  • Compared to 1 year ago, EXE has an improved debt to assets ratio.
EXE.CA Yearly Shares OutstandingEXE.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
EXE.CA Yearly Total Debt VS Total AssetsEXE.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • EXE has an Altman-Z score of 3.44. This indicates that EXE is financially healthy and has little risk of bankruptcy at the moment.
  • EXE has a Altman-Z score of 3.44. This is amongst the best in the industry. EXE outperforms 85.71% of its industry peers.
  • The Debt to FCF ratio of EXE is 3.39, which is a good value as it means it would take EXE, 3.39 years of fcf income to pay off all of its debts.
  • EXE has a Debt to FCF ratio of 3.39. This is in the better half of the industry: EXE outperforms 78.57% of its industry peers.
  • EXE has a Debt/Equity ratio of 1.94. This is a high value indicating a heavy dependency on external financing.
  • EXE's Debt to Equity ratio of 1.94 is on the low side compared to the rest of the industry. EXE is outperformed by 64.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.94
Debt/FCF 3.39
Altman-Z 3.44
ROIC/WACC2.4
WACC7.72%
EXE.CA Yearly LT Debt VS Equity VS FCFEXE.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • EXE has a Current Ratio of 0.81. This is a bad value and indicates that EXE is not financially healthy enough and could expect problems in meeting its short term obligations.
  • EXE's Current ratio of 0.81 is in line compared to the rest of the industry. EXE outperforms 57.14% of its industry peers.
  • A Quick Ratio of 0.81 indicates that EXE may have some problems paying its short term obligations.
  • With a decent Quick ratio value of 0.81, EXE is doing good in the industry, outperforming 64.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.81
EXE.CA Yearly Current Assets VS Current LiabilitesEXE.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • EXE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.52%, which is quite impressive.
  • The Earnings Per Share has been growing by 22.74% on average over the past years. This is a very strong growth
  • Looking at the last year, EXE shows a quite strong growth in Revenue. The Revenue has grown by 11.59% in the last year.
  • EXE shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.31% yearly.
EPS 1Y (TTM)52.52%
EPS 3Y92.12%
EPS 5Y22.74%
EPS Q2Q%65.04%
Revenue 1Y (TTM)11.59%
Revenue growth 3Y7.91%
Revenue growth 5Y5.31%
Sales Q2Q%22.62%

3.2 Future

  • EXE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.75% yearly.
  • The Revenue is expected to grow by 10.83% on average over the next years. This is quite good.
EPS Next Y33.67%
EPS Next 2Y21.07%
EPS Next 3Y19.7%
EPS Next 5Y9.75%
Revenue Next Year15.35%
Revenue Next 2Y25.35%
Revenue Next 3Y18.26%
Revenue Next 5Y10.83%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EXE.CA Yearly Revenue VS EstimatesEXE.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B 2B
EXE.CA Yearly EPS VS EstimatesEXE.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 23.07, the valuation of EXE can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of EXE indicates a somewhat cheap valuation: EXE is cheaper than 78.57% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.92, EXE is valued at the same level.
  • With a Price/Forward Earnings ratio of 20.51, EXE is valued on the expensive side.
  • EXE's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. EXE is cheaper than 78.57% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.78, EXE is valued a bit cheaper.
Industry RankSector Rank
PE 23.07
Fwd PE 20.51
EXE.CA Price Earnings VS Forward Price EarningsEXE.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, EXE is valued a bit cheaper than 78.57% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, EXE is valued a bit cheaper than 64.29% of the companies in the same industry.
Industry RankSector Rank
P/FCF 20.17
EV/EBITDA 13.27
EXE.CA Per share dataEXE.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • EXE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • EXE has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as EXE's earnings are expected to grow with 19.70% in the coming years.
PEG (NY)0.69
PEG (5Y)1.01
EPS Next 2Y21.07%
EPS Next 3Y19.7%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. Dividend

5.1 Amount

  • EXE has a Yearly Dividend Yield of 2.16%.
  • Compared to an average industry Dividend Yield of 1.35, EXE pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.83, EXE has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.16%

5.2 History

  • The dividend of EXE has a limited annual growth rate of 2.79%.
  • EXE has been paying a dividend for at least 10 years, so it has a reliable track record.
  • EXE has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)2.79%
Div Incr Years1
Div Non Decr Years3
EXE.CA Yearly Dividends per shareEXE.CA Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.1 0.2 0.3 0.4 0.5

5.3 Sustainability

  • 45.22% of the earnings are spent on dividend by EXE. This is a bit on the high side, but may be sustainable.
  • The dividend of EXE is growing, but earnings are growing more, so the dividend growth is sustainable.
DP45.22%
EPS Next 2Y21.07%
EPS Next 3Y19.7%
EXE.CA Yearly Income VS Free CF VS DividendEXE.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M
EXE.CA Dividend Payout.EXE.CA Dividend Payout, showing the Payout Ratio.EXE.CA Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

EXTENDICARE INC

TSX:EXE (2/6/2026, 7:00:00 PM)

23.99

-0.22 (-0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-11
Earnings (Next)02-26
Inst Owners24.82%
Inst Owner ChangeN/A
Ins Owners0.96%
Ins Owner ChangeN/A
Market Cap2.01B
Revenue(TTM)1.59B
Net Income(TTM)91.00M
Analysts78
Price Target24.69 (2.92%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.16%
Yearly Dividend0.48
Dividend Growth(5Y)2.79%
DP45.22%
Div Incr Years1
Div Non Decr Years3
Ex-Date01-30
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.02%
PT rev (3m)46.61%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.37%
EPS NY rev (3m)6.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.84%
Valuation
Industry RankSector Rank
PE 23.07
Fwd PE 20.51
P/S 1.26
P/FCF 20.17
P/OCF 13.16
P/B 12.27
P/tB N/A
EV/EBITDA 13.27
EPS(TTM)1.04
EY4.34%
EPS(NY)1.17
Fwd EY4.88%
FCF(TTM)1.19
FCFY4.96%
OCF(TTM)1.82
OCFY7.6%
SpS18.97
BVpS1.96
TBVpS-0.41
PEG (NY)0.69
PEG (5Y)1.01
Graham Number6.76
Profitability
Industry RankSector Rank
ROA 10.41%
ROE 55.53%
ROCE 24.53%
ROIC 18.54%
ROICexc 26.92%
ROICexgc 58.63%
OM 8.22%
PM (TTM) 5.72%
GM 14.15%
FCFM 6.27%
ROA(3y)8.13%
ROA(5y)6.26%
ROE(3y)56.07%
ROE(5y)44.35%
ROIC(3y)11.4%
ROIC(5y)10.15%
ROICexc(3y)15.38%
ROICexc(5y)13.52%
ROICexgc(3y)24.33%
ROICexgc(5y)19.82%
ROCE(3y)15.09%
ROCE(5y)13.42%
ROICexgc growth 3Y72.34%
ROICexgc growth 5Y37.48%
ROICexc growth 3Y55.61%
ROICexc growth 5Y29.1%
OM growth 3Y21.21%
OM growth 5Y10.26%
PM growth 3Y73.29%
PM growth 5Y15.22%
GM growth 3Y6.44%
GM growth 5Y3.11%
F-Score6
Asset Turnover1.82
Health
Industry RankSector Rank
Debt/Equity 1.94
Debt/FCF 3.39
Debt/EBITDA 1.91
Cap/Depr 150.97%
Cap/Sales 3.34%
Interest Coverage 9.89
Cash Conversion 92.12%
Profit Quality 109.55%
Current Ratio 0.81
Quick Ratio 0.81
Altman-Z 3.44
F-Score6
WACC7.72%
ROIC/WACC2.4
Cap/Depr(3y)281.27%
Cap/Depr(5y)221.87%
Cap/Sales(3y)7.03%
Cap/Sales(5y)5.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.52%
EPS 3Y92.12%
EPS 5Y22.74%
EPS Q2Q%65.04%
EPS Next Y33.67%
EPS Next 2Y21.07%
EPS Next 3Y19.7%
EPS Next 5Y9.75%
Revenue 1Y (TTM)11.59%
Revenue growth 3Y7.91%
Revenue growth 5Y5.31%
Sales Q2Q%22.62%
Revenue Next Year15.35%
Revenue Next 2Y25.35%
Revenue Next 3Y18.26%
Revenue Next 5Y10.83%
EBIT growth 1Y30.7%
EBIT growth 3Y30.79%
EBIT growth 5Y16.11%
EBIT Next Year10.8%
EBIT Next 3Y17.11%
EBIT Next 5Y9.15%
FCF growth 1Y199.78%
FCF growth 3YN/A
FCF growth 5Y53.33%
OCF growth 1Y343.54%
OCF growth 3Y31.32%
OCF growth 5Y26.02%

EXTENDICARE INC / EXE.CA FAQ

What is the fundamental rating for EXE stock?

ChartMill assigns a fundamental rating of 6 / 10 to EXE.CA.


What is the valuation status for EXE stock?

ChartMill assigns a valuation rating of 6 / 10 to EXTENDICARE INC (EXE.CA). This can be considered as Fairly Valued.


What is the profitability of EXE stock?

EXTENDICARE INC (EXE.CA) has a profitability rating of 8 / 10.


Can you provide the expected EPS growth for EXE stock?

The Earnings per Share (EPS) of EXTENDICARE INC (EXE.CA) is expected to grow by 33.67% in the next year.


Is the dividend of EXTENDICARE INC sustainable?

The dividend rating of EXTENDICARE INC (EXE.CA) is 5 / 10 and the dividend payout ratio is 45.22%.